Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | SCN4A | P35499 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5242188 | 1.00 | LTA4H (0.54) | LTA4HSIGMAR1SCN4AALDH1A1KDM4E | |
| Tert-Butyl Formate SCHEMBL27699395 | 0.90 | LTA4H (0.48) | LTA4HSIGMAR1SCN4AALDH1A1KDM4E | |
| Tert-Butyl Formate SCHEMBL27699397 | 0.90 | LTA4H (0.48) | LTA4HSIGMAR1SCN4AALDH1A1KDM4E | |
| SCHEMBL3493009 | 0.89 | LTA4H (0.56) | LTA4HSIGMAR1ALDH1A1KDM4ECYP2D6 | |
| SCHEMBL3626359 | 0.89 | LTA4H (0.56) | LTA4HSIGMAR1ALDH1A1KDM4ECYP2D6 | |
| SCHEMBL25154290 | 0.89 | LTA4H (0.56) | LTA4HSIGMAR1ALDH1A1KDM4ECYP2D6 | |
| SCHEMBL10674002 | 0.86 | LTA4H (0.54) | LTA4HSIGMAR1ALDH1A1KDM4ELMNA | |
| SCHEMBL691443 | 0.86 | LTA4H (0.54) | LTA4HSIGMAR1SCN4AGAAPKM | |
| SCHEMBL691646 | 0.86 | LTA4H (0.54) | LTA4HSIGMAR1SCN4AGAAPKM | |
| Hydrochloric Acid SCHEMBL30412643 | 0.85 | LTA4H (0.53) | LTA4HSIGMAR1SCN4AGAAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070249616-A1 | Substituted 1-Benzyl-4-Substituted Piperazine Analogues | NEUROGEN CORPORATION (US) | 2007-10-25 | — | — | US | disclosed |
| US-7253168-B2 | Substituted 1-benzyl-4-substituted piperazine analogues | NEUROGEN CORPORATION (US) | 2007-08-07 | — | — | US | disclosed |
| US-20060142301-A1 | Substituted 1-benzyl-4-substituted piperazine analogues | NEUROGEN CORPORATION | 2006-06-29 | — | — | US | disclosed |
| US-20060009456-A1 | Aryl-substituted piperazine derivatives | NEUROGEN CORPORATION | 2006-01-12 | — | — | US | disclosed |
| US-20050239791-A1 | Substituted 1-heteroaryl-4-substituted piperazine and piperidine analogues | NEUROGEN CORPORATION | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239791-A1 | Substituted 1-heteroaryl-4-substituted piperazine and piperidine analogues | MCHR1, MCHR2, PRLHR | LTA4H 2026/4885SIGMAR1 54/4885SCN4A 1763/4885 |
| US-20070249616-A1 | Substituted 1-Benzyl-4-Substituted Piperazine Analogues | MCHR1, MCHR2, PRLHR | LTA4H 2241/4885SIGMAR1 64/4885SCN4A 1377/4885 |
| US-20060009456-A1 | Aryl-substituted piperazine derivatives | MCHR1, MCHR2, PRLHR | LTA4H 2476/4885SIGMAR1 120/4885SCN4A 2961/4885 |
| US-20060142301-A1 | Substituted 1-benzyl-4-substituted piperazine analogues | MCHR1, MCHR2, PRLHR | LTA4H 2241/4885SIGMAR1 64/4885SCN4A 1377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.